Preclinical prediction of factors influencing the elimination of 5,6- dimethylxanthenone-4-acetic acid, a new anticancer drug

Cancer Research

Volumn 57, Issue 2, 1997, Pages 284-289

  Miners, John O ^a   Valente, Leanne ^a   Lillywhite, Karen J ^a   Mackenzie, Peter I ^a   Burchell, Brian ^b   Baguley, Bruce C ^c   Kestell, Philip ^c  

^a FLINDERS MEDICAL CENTRE   (Australia)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; AMITRIPTYLINE; ANTINEOPLASTIC AGENT; CODEINE; COMPLEMENTARY DNA; CYCLIZINE; CYCLOBENZAPRINE; DICLOFENAC; EPIRUBICIN; INDOMETACIN; KETOPROFEN; LAMOTRIGINE; LORAZEPAM; MICROSOME ENZYME; MORPHINE; NAPROXEN; OXAZEPAM; PARACETAMOL; PHENYLBUTAZONE; PROBENECID; SALICYLIC ACID; TEMAZEPAM; TRIPELENNAMINE; VALPROIC ACID; ZIDOVUDINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG DEGRADATION; DRUG DISPOSITION; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; LIVER METABOLISM; LIVER MICROSOME; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; GLUCURONATES; HALF-LIFE; HUMANS; MICROSOMES, LIVER; XANTHENES; XANTHONES;

EID: 0031022925     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Evans, W. E., and Relling, M. V. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin. Pharmacokinet., 16: 327-336, 1989.
2. Kivisto, K. T., Kroemer, H. K., and Eichelbaum, M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br. J. Clin. Pharmacol., 40: 523-530, 1995.
3. Miners, J. O., Veronese, M. E., and Birkett, D. J. In vitro approaches for the prediction of human drug metabolism. Annu. Rep. Med. Chem., 29: 307-316, 1994.
4. Birkett, D. J., Mackenzie, P. I., Veronese, M. E., and Miners, J. O. In vitro approaches can predict human drug metabolism. Trends Pharmacol. Sci., 14: 292-295, 1993.
5. Rewcastle, G. W., Atwell, G. J., Zhuang, L., Baguley, B. C., and Denny, W. A. Potential antitumor agents: 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J. Med. Chem., 34: 217-222, 1991.
6. McKeage, M. J., Kestell, P., Denny, W. A., and Baguley, B. C. Plasma pharmacokinetics of the antitumor agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid, and flavone-8-acetic acid in mice. Cancer Chemother. Pharmacol., 28: 409-413, 1991.
7. Kestell, P., Rewcastle, G. W., and Baguley, B. C. Disposition of the novel antitumor agent xanthenone-4-acetic acid in the mouse: identification of metabolites and routes of elimination. Xenobiotica, 24: 635-647, 1994.
8. Webster, L. K., Ellis, A. G., Kestell, P., and Rewcastle, G. W. Metabolism and elimination of 5,6-dimethylxanthenone-4-acetic acid in the isolated perfused rat liver. Drug Metab. Dispos., 23: 363-368, 1995.
9. McManus, M. E., Burgess, W. M., Veronese, M. E., Hugget, A., Quattrochi, L. M., and Tukey, R. H. Metabolism of 2-acetylaminofluorene and benzo(a)pyrene and activation of food-derived heterocyclic amine mutagens by human cytochromes P450. Cancer Res., 50: 3367-3376, 1990.
10. Robson, R. A., Matthews, A. P., Miners, J. O., McManus, M. E., Meyer, U. A., Hall, P. D., and Birkett, D. J. Characterisation of theophylline metabolism by human liver microsomes. Br. J. Clin. Pharmacol., 24: 293-300, 1987.
11. Jin, C-J., Miners, J. O., Lillywhite, K. J., and Mackenzie, P. I. cDNA cloning and expression of a human liver UDP-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. J. Pharmacol. Exp. Ther., 264: 475-479, 1993.
12. Jin, C-J., Miners, J. O., Lillywhite, K. J., and Mackenzie, P. I. cDNA cloning and expression of two new members of the human liver UDP-glucuronosyltransferase 2B subfamily. Biochem. Biophys. Res. Commun., 194: 496-503, 1993.
13. Harding, D., Fournel-Grigleux, S., Jackson, M. R., and Burchell, B. Cloning and substrate specificity of a human phenol UDP-glucuronosyltransferase expressed in COS-7 cells. Proc. Natl. Acad. Sci. USA, 55: 8381-8385, 1988.
14. Wooster, R., Sutherland, L., Ebner, T., Clarke, D., DaCruz, E., Silva, O., and Burchell, B. Cloning and stable expression of a new member of the human liver phenol/bilirubin UDP-glucuronosyltransferase cDNA family. Biochem. J., 278: 465-469, 1991.
15. Lowry, O. H., Rosebrough, N. J., Fair, A. L., and Randall, A. J. Protein measurement with the Folin-phenol reagent. J. Biol. Chem., 193: 265-275, 1951.
16. Miners, J. O., and Mackenzie, P. I. Drug glucuronidation in humans. Pharmacol. Ther., 54: 347-369, 1991.
17. Day, R. O., Graham, G. G., Williams, K. M., Champion, G. D., and de Jaeger, J. Clinical pharmacology of the non-steroidal anti-inflammatory drugs. Pharmacol. Ther., 43: 480-487, 1988.
18. Verbeeck, R. K., Blackburn, J. L., and Loewen, G. R. Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs. Clin. Pharmacokinetics, 8: 297-331, 1983.
19. Greenblatt, D. J. Clinical pharmacokinetics of oxazepam and lorazepam. Clin. Pharmacokinet., 6: 89-105, 1981.
20. Divoll, M., Greenblatt, D. J., Harmatz, J., and Shader, R. I. Effect of age and gender on the disposition of temazepam. J. Pharm. Sci., 70: 1104-1107, 1981.
21. Plosker, M., and Faulds, D. Epirubicin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in cancer chemotherapy. Drugs, 45: 788-856, 1993.
22. Spahn-Langguth, H., and Benet, L. Z. Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab. Rev., 24: 5-48, 1992.
23. Meffin, P. J., Zilm, D. M., and Veenendaal, J. R. Reduced clofibric acid clearance in renal dysfunction is due to a futile cycle. J. Pharmacol. Exp. Ther., 227: 732-736, 1983.
24. Ebner, T., and Burchell, B. Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGT1 gene family. Drug Metab. Dispos., 21: 50-53, 1993.
25. Ritter, J. K., Chen, F., Sheen, Y. Y., Lubet, R. A., and Owens, I. S. Two human liver cDNAs encode UDP-glucuronosyltransferases with 2 log differences in activity toward parallel substrates including hyodeoxycholic acid and estrogen derivatives. Biochemistry, 31: 3409-3414, 1992.
26. Sutherland, L., Ebner, T., and Burchell, B. The expression of UDP-glucuronosyl-transferases of the UGT1 family in human liver and kidney and in response to drugs. Biochem. Pharmacol., 45: 295-301, 1993.